LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer.

已取消 10 由落地人参果发布于 2024/4/19 17:20:02

DOI:10.1200/JCO.2014.32.15_SUPPL.534
作者：A. Patnaik, L. Rosen, S. Tolaney, A. Tolcher, J. Goldman, L. Gandhi, K. Papadopoulos, M. Beeram, D. Rasco, S. Myrand, P. Kulanthaivel, Joan M. Andrews, Martin Frenzel, D. Cronier, E. Chan, K. Flaherty, P. Wen, G. Shapiro
文献类型：期刊论文
补充材料：只需要正文

American Society of Clinical Oncology (ASCO)

Abstract：534 Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) act with D-type cyclins to enable cell proliferation. LY2835219, a small molecule inhibitor of CDK4/6, has shown antitumor activity

应助信息

2024-04-19

Book学术机器人

2024/4/19 17:20:02 未找到该文献，机器人已退出，请等待人工下载

2024/4/19 17:20:02 Book学术AI机器人收到请求，开始寻找文献

2024/4/19 17:20:02 已向机器人发送请求

2024-04-19

落地人参果发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:知网改性金属有机框架光催化剂制备及水处理效能